MLYS vs. LQDA
MLYS (Mineralys Therapeutics Inc. Common Stock) and LQDA (Liquidia Corporation) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, MLYS returned 16.73%/yr vs 103.18%/yr for LQDA. At a 0.21 correlation, their price movements are largely independent.
Performance
MLYS vs. LQDA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MLYS achieves a -30.09% return, which is significantly lower than LQDA's 118.88% return.
MLYS
- 1D
- 3.00%
- 1M
- -15.01%
- YTD
- -30.09%
- 6M
- -32.45%
- 1Y
- 88.20%
- 3Y*
- 16.73%
- 5Y*
- —
- 10Y*
- —
LQDA
- 1D
- 6.22%
- 1M
- 23.79%
- YTD
- 118.88%
- 6M
- 110.98%
- 1Y
- 473.20%
- 3Y*
- 103.18%
- 5Y*
- 94.96%
- 10Y*
- —
MLYS vs. LQDA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
MLYS Mineralys Therapeutics Inc. Common Stock | -30.09% | 194.80% | 43.14% | -59.24% |
LQDA Liquidia Corporation | 118.88% | 193.28% | -2.24% | 75.88% |
Correlation
The correlation between MLYS and LQDA is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Feb 10, 2023 | 0.21 |
Fundamentals
MLYS:
$2.10B
LQDA:
$7.63B
MLYS:
-$2.03
LQDA:
$0.24
MLYS:
3.29
LQDA:
70.30
MLYS:
$0.00
LQDA:
$288.07M
MLYS:
-$28.00K
LQDA:
$275.77M
MLYS:
-$167.25M
LQDA:
$51.53M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MLYS vs. LQDA — Risk / Return Rank
MLYS
LQDA
MLYS vs. LQDA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Mineralys Therapeutics Inc. Common Stock (MLYS) and Liquidia Corporation (LQDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MLYS | LQDA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -6.38 | ||
| Sortino ratioReturn per unit of downside risk | -2.79 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.67 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | 1.69 | 13.38 | -11.69 |
| Martin ratioReturn relative to average drawdown | 3.10 | 34.60 | -31.50 |
Loading charts...
Drawdowns
MLYS vs. LQDA - Drawdown Comparison
The maximum MLYS drawdown since its inception was -71.75%, smaller than the maximum LQDA drawdown of -93.87%. Use the drawdown chart below to compare losses from any high point for MLYS and LQDA.
Loading charts...
Drawdown Indicators
| MLYS | LQDA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -71.75% | -93.87% | +22.12% |
Max Drawdown (1Y)Largest decline over 1 year | -52.46% | -35.66% | -16.80% |
Max Drawdown (3Y)Largest decline over 3 years | -65.15% | -46.80% | -18.35% |
Max Drawdown (5Y)Largest decline over 5 years | — | -55.36% | — |
Current DrawdownCurrent decline from peak | -46.40% | 0.00% | -46.40% |
Average DrawdownAverage peak-to-trough decline | -36.37% | -69.36% | +32.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.56% | 13.76% | +14.80% |
Volatility
MLYS vs. LQDA - Volatility Comparison
Mineralys Therapeutics Inc. Common Stock (MLYS) has a higher volatility of 22.12% compared to Liquidia Corporation (LQDA) at 20.00%. This indicates that MLYS's price experiences larger fluctuations and is considered to be riskier than LQDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MLYS | LQDA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.12% | 20.00% | +2.12% |
Volatility (6M)Calculated over the trailing 6-month period | 44.28% | 48.89% | -4.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 106.21% | 66.28% | +39.93% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 83.32% | 73.81% | +9.51% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.32% | 85.75% | -2.43% |
Dividends
MLYS vs. LQDA - Dividend Comparison
Neither MLYS nor LQDA has paid dividends to shareholders.
Financials
MLYS vs. LQDA - Financials Comparison
This section allows you to compare key financial metrics between Mineralys Therapeutics Inc. Common Stock and Liquidia Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MLYS and LQDA have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MLYS has higher volatility (22.12%) compared to LQDA (20.00%). In terms of maximum drawdown, MLYS dropped -71.75% vs LQDA's -93.87%.
LQDA currently has the higher Sharpe Ratio (7.21 vs 0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MLYS and LQDA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer